ORIC Pharma Collaborates With Pfizer For Phase 2 Study Of ORIC-533 In Multiple Myeloma; Stock Up
NEW YORK CITY (dpa-AFX) - ORIC Pharmaceuticals Inc. (ORIC) said that it has reached a clinical development collaboration with Pfizer for a potential phase 2 study of ORIC-533 in multiple myeloma.ORIC
Source: finanznachrichten.de